Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Long-Term Debt Repayments (2022)

Xeris Biopharma Holdings (XERS) has disclosed Long-Term Debt Repayments for 1 consecutive years, with $43.5 million as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Long-Term Debt Repayments changed N/A year-over-year to $43.5 million, compared with a TTM value of $43.5 million through Dec 2022, changed N/A, and an annual FY2022 reading of $43.5 million, changed N/A over the prior year.
  • Long-Term Debt Repayments was $43.5 million for Q1 2022 at Xeris Biopharma Holdings.
  • Across five years, Long-Term Debt Repayments topped out at $43.5 million in Q1 2022 and bottomed at $43.5 million in Q1 2022.